Associations - NTRK2 fusion

NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	entrectinib Sensitive: A1 - Approval ASCO 2022 - 3 days (NewA1)	entrectinib Sensitive: A1 - Approval ASCO 2022 - 3 days - (New C3)
NTRK2 fusion NTRK2 fusion	Breast Cancer Breast Cancer	NTRK2 fusion NTRK2 fusion	Breast Cancer Breast Cancer	entrectinib Sensitive: A2 - Guideline ESMO-BC 2022 - 3 weeks (NewA2)	entrectinib Sensitive: A2 - Guideline ESMO-BC 2022 - 3 weeks - (New C3)
NTRK2 fusion NTRK2 fusion	Sarcoma Sarcoma	NTRK2 fusion NTRK2 fusion	Sarcoma Sarcoma	larotrectinib Sensitive: A1 - Approval	larotrectinib Sensitive: A1 - Approval
NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	larotrectinib Sensitive: A1 - Approval	larotrectinib Sensitive: A1 - Approval
NTRK2 fusion NTRK2 fusion	Small Intestinal Carcinoma Small Intestinal Carcinoma	NTRK2 fusion NTRK2 fusion	Small Intestinal Carcinoma Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastrointestinal Stromal Tumor GIST	NTRK2 fusion NTRK2 fusion	Gastrointestinal Stromal Tumor GIST	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Peritoneal Cancer Peritoneal Cancer	NTRK2 fusion NTRK2 fusion	Peritoneal Cancer Peritoneal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Peritoneal Cancer Peritoneal Cancer	NTRK2 fusion NTRK2 fusion	Peritoneal Cancer Peritoneal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Fallopian Tube Cancer Fallopian Tube Cancer	NTRK2 fusion NTRK2 fusion	Fallopian Tube Cancer Fallopian Tube Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Fallopian Tube Cancer Fallopian Tube Cancer	NTRK2 fusion NTRK2 fusion	Fallopian Tube Cancer Fallopian Tube Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Sarcoma Sarcoma	NTRK2 fusion NTRK2 fusion	Sarcoma Sarcoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Small Intestinal Carcinoma Small Intestinal Carcinoma	NTRK2 fusion NTRK2 fusion	Small Intestinal Carcinoma Small Intestinal Carcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	NTRK2 fusion NTRK2 fusion	Pancreatic Cancer Pancreatic Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastrointestinal Stromal Tumor GIST	NTRK2 fusion NTRK2 fusion	Gastrointestinal Stromal Tumor GIST	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Soft Tissue Sarcoma Soft Tissue Sarcoma	NTRK2 fusion NTRK2 fusion	Soft Tissue Sarcoma Soft Tissue Sarcoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	NTRK2 fusion NTRK2 fusion	Esophageal Cancer Esophageal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Soft Tissue Sarcoma Soft Tissue Sarcoma	NTRK2 fusion NTRK2 fusion	Soft Tissue Sarcoma Soft Tissue Sarcoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	NTRK2 fusion NTRK2 fusion	Biliary Tract Cancer Biliary Tract Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Breast Cancer Breast Cancer	NTRK2 fusion NTRK2 fusion	Breast Cancer Breast Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Melanoma Melanoma	NTRK2 fusion NTRK2 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	NTRK2 fusion NTRK2 fusion	Hepatocellular Cancer HCC	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Ovarian Cancer Ovarian Cancer	NTRK2 fusion NTRK2 fusion	Ovarian Cancer Ovarian Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Ovarian Cancer Ovarian Cancer	NTRK2 fusion NTRK2 fusion	Ovarian Cancer Ovarian Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Salivary Gland Cancer Salivary Gland Cancer	NTRK2 fusion NTRK2 fusion	Salivary Gland Cancer Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Salivary Gland Cancer Salivary Gland Cancer	NTRK2 fusion NTRK2 fusion	Salivary Gland Cancer Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastric Cancer Gastric Cancer	NTRK2 fusion NTRK2 fusion	Gastric Cancer Gastric Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Gastric Cancer Gastric Cancer	NTRK2 fusion NTRK2 fusion	Gastric Cancer Gastric Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cutaneous Melanoma Cutaneous Melanoma	NTRK2 fusion NTRK2 fusion	Cutaneous Melanoma Cutaneous Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cutaneous Melanoma Cutaneous Melanoma	NTRK2 fusion NTRK2 fusion	Cutaneous Melanoma Cutaneous Melanoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioma Glioma	NTRK2 fusion NTRK2 fusion	Glioma Glioma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	NTRK2 fusion NTRK2 fusion	Rectal Cancer Rectal Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioma Glioma	NTRK2 fusion NTRK2 fusion	Glioma Glioma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Vulvar Cancer Vulvar Cancer	NTRK2 fusion NTRK2 fusion	Vulvar Cancer Vulvar Cancer	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Vulvar Cancer Vulvar Cancer	NTRK2 fusion NTRK2 fusion	Vulvar Cancer Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	TPX-0005 Sensitive: B - Late Trials	TPX-0005 Sensitive: B - Late Trials
NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	Trk inhibitor Sensitive: B - Late Trials	Trk inhibitor Sensitive: B - Late Trials
NTRK2 fusion NTRK2 fusion	Lung Cancer Lung Cancer	NTRK2 fusion NTRK2 fusion	Lung Cancer Lung Cancer	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Gastrointestinal Cancer Gastrointestinal Cancer	NTRK2 fusion NTRK2 fusion	Gastrointestinal Cancer Gastrointestinal Cancer	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Small Cell Lung Cancer Small Cell Lung Cancer	NTRK2 fusion NTRK2 fusion	Small Cell Lung Cancer Small Cell Lung Cancer	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Fibrosarcoma Fibrosarcoma	NTRK2 fusion NTRK2 fusion	Fibrosarcoma Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Osteosarcoma Osteosarcoma	NTRK2 fusion NTRK2 fusion	Osteosarcoma Osteosarcoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	NTRK2 fusion NTRK2 fusion	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	NTRK2 fusion NTRK2 fusion	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Colon Cancer Colon Cancer	NTRK2 fusion NTRK2 fusion	Colon Cancer Colon Cancer	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	CNS Tumor CNS Tumor	NTRK2 fusion NTRK2 fusion	CNS Tumor CNS Tumor	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
NTRK2 fusion NTRK2 fusion	Glioma Glioma	NTRK2 fusion NTRK2 fusion	Glioma Glioma	trametinib + entrectinib Sensitive: D – Preclinical	trametinib + entrectinib Sensitive: D – Preclinical
NTRK2 fusion NTRK2 fusion	Glioma Glioma	NTRK2 fusion NTRK2 fusion	Glioma Glioma	entrectinib + abemaciclib Sensitive: D – Preclinical	entrectinib + abemaciclib Sensitive: D – Preclinical
NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	NTRK2 fusion NTRK2 fusion	Solid Tumor Solid Tumor	SIM1803-1A Sensitive: D – Preclinical	SIM1803-1A Sensitive: D – Preclinical